Quantcast

Latest Merck Serono Stories

2014-09-19 04:21:46

ROCKLAND, Massachusetts, September 19, 2014 /PRNewswire/ -- - The first grants awarded to coincide with the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting - Investment supports innovative projects for the advancement of science and medical research in the field of growth EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the first recipients of the Grant for Growth Innovation (GGI) for...

2014-09-17 08:29:31

- Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand its oncology pipeline SAN FRANCISCO, Sept. 17, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and...

2014-09-11 12:22:23

-- Providing IVF clinicians objective embryo viability data and another tool to support patient outcomes MISSISSAUGA, ON, Sept. 11, 2014 /CNW/ - EMD Serono, Canada, a subsidiary of Merck KGaA Darmstadt, Germany announced today the launch of the Eeva (®) Test in Canada. In April, Merck Serono, a biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced an exclusive licensing agreement with Auxogyn Inc. for the rights to commercialize the Eeva (®) Test in Europe...

2014-09-09 16:25:56

- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression, and 'no evident disease activity' (NEDA) measure for interferon beta-1a SC vs. interferon beta-1a IM ROCKLAND, Mass., Sept. 9, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the division's multiple sclerosis...

2014-09-08 08:31:07

BOSTON, Sept. 8, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that Merck Serono has completed a routine license renewal for CRINONE in one of its biggest markets. CRINONE is Columbia's largest revenue stream and shipments to this high-growth, high-volume market were...

2014-09-02 08:31:32

ROCKLAND, Mass., Sept. 2, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products. http://photos.prnewswire.com/prnvar/20140902/141784 Bringing more than 20 years of experience leading global and...

2014-08-29 08:24:31

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous...

2014-08-27 08:28:17

BOSTON, Aug. 27, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it will participate at the upcoming Rodman & Renshaw 16(th) Annual Global Investment Conference, to be held in New York. The Company will present at the conference at 11:15am on September 9, 2014 at...

2014-08-06 08:32:38

BOSTON, Aug. 6, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Lil' Drug Store Products exercised its option to purchase the Intellectual Property Rights and Technology related to Legatrin P.M. Columbia licensed this product to Lil' Drug Store Products approximately fourteen years ago and has received annual royalties. Based on a predetermined formula, Columbia will receive approximately $2.2 million for the sale. "Columbia has a long history of...

2014-07-31 08:35:09

BOSTON, July 31, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company") today announced financial results for the three and six-month periods ended June 30, 2014. "Second quarter results benefited from the contribution of the Molecular Profiles services business, as its diversified revenue stream partially offset an anticipated and temporary decline in product revenues from Merck Serono during a routine license renewal in one high-volume, high-margin...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related